Skip to main content
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Subscribe
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Articles
Conference Correspondent
,
ASH 2016 - Chronic Lymphocytic Leukemia
Reviewing the Demographics and First-Line Treatment Patterns in Patients with CLL
Read More
Conference Correspondent
,
ASH 2016 - Chronic Lymphocytic Leukemia
Phase 1b Results of a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Read More
Conference Correspondent
,
ASH 2016 - Chronic Lymphocytic Leukemia
Changes in Clinical Stage Identify Different Response Categories Among Patients in iwCLL PR: Analysis of CLL Patients on the RESONATE Study
Read More
Conference Correspondent
,
ASH 2016 - Chronic Lymphocytic Leukemia
PD-1 Blockade with Pembrolizumab in Relapsed CLL Including Richter’s Transformation: An Updated Report from a Phase 2 Trial (MC1485)
Read More
Conference Correspondent
,
ASH 2016 - Chronic Lymphocytic Leukemia
Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Read More
Conference Correspondent
,
ASH 2016 - Chronic Lymphocytic Leukemia
Identification of Baseline Characteristics That Predict Good Outcome of alloHCT in Young CLL Patients - A Retrospective Analysis from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
Read More
Conference Correspondent
,
ASH 2016 - Chronic Lymphocytic Leukemia
Preclinical Analyses Support Clinical Investigation of Combined Anti-CD19 CAR-T Cell, JCAR017 with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia
Read More
Conference Correspondent
,
ASH 2016 - Chronic Lymphocytic Leukemia
Long-Term Follow-Up of Chlorambucil plus Rituximab Combination as Frontline Therapy for Elderly and/or Unfit Patients with CLL, Including Risk Stratification
Read More
Conference Correspondent
,
ASH 2016 - Chronic Lymphocytic Leukemia
Management and Outcomes of Atrial Fibrillation in Patients Receiving Ibrutinib for Hematologic Malignancies at a Single Center
Read More
Conference Correspondent
,
ASH 2016 - Chronic Lymphocytic Leukemia
Initial Results of a Multicenter, Phase II Study of Ibrutinib plus FCR (iFCR) as Frontline Therapy for Younger CLL Patients
Read More
100
101
102
103
104
105
106
Page 103 of 244
Results 1021 - 1030 of 2434